Phase II Data Of Medigen COVID-19 Vaccine, Reviewed And Publis... - 15 October 2021 22:22

TAIPEI,Oct.15,2021/PRNewswire-AsiaNet/-- The Lancet Respiratory Medicine(https://www.thelancet.com/journals/lanres/article/PIIS2213-2600(21)00402-1/fulltext), one of the world's best-known peer-reviewed medical journals has published Medigen Vaccine Biologics(https://www.medigenvac.com/p...

  Gan & Lee Pharmaceuticals Concludes Phase 3 Studies of Gan & L... - 15 October 2021 00:33

BEIJING and BRIDGEWATER, N.J., Oct. 14 2021 /PRNewswire-AsiaNet/ -- Gan & Lee Pharmaceuticals Co., Ltd. (hereinafter referred to as Gan & Lee) (Shanghai: 603087.SH), is pleased to announce the completion of two randomized, multicenter, phase 3 studies that compare proposed biosimilar Gan & Lee insulin glargine (GL...

  Berry Oncology Releases Latest Research Results on Early Scree... - 14 October 2021 00:03

SHANGHAI, Oct. 13, 2021 /PRNewswire-AsiaNet/ -- -Head of the Chinese oncology genomic testing company shared their recent findings on early screening for multiple high-risk cancers Berry Oncology, a Chinese oncology genomic testing company, was invited to the inaugural International Biopharm...

  Vitality International - Pioneering Algorithm Calculates The N... - 13 October 2021 02:20

LONDON, October 13, 2021 /PRNewswire-AsiaNet/-- - Research shows number of years people are spending in ill health is increasing, due to the rising prevalence of chronic diseases, driven by unhealthy lifestyles - Experts call for focus on healthspan, the quality of life, alongside lifespan,...

  DarwinHealth Announces Scientific Collaboration with Prelude T... - 13 October 2021 01:55

NEW YORK, Oct. 13, 2021 /PRNewswire-AsiaNet/ -- DarwinHealth, Inc. today announced a scientific research collaboration employing its Biomarker Enrichment Strategies for Trials (BEST platform) to elucidate novel biomarkers to guide translational trajectories for multiple oncology molecules being...

  CBC-backed Jadeite Medicines Announces Exclusive Licensing Agr... - 12 October 2021 23:31

TOKYO, Oct. 12, 2021 /PRNewswire-AsiaNet/ -- - Agreement to accelerate the development and commercialization of odevixibat in Japan, a significant market for PFIC, Alagille syndrome and biliary atresia - Bylvay™ (odevixibat) approved in U.S., EU and UK with global prescriptions already gen...

  Eleva Enters Clinical Development of Difficult-To-Express High... - 12 October 2021 10:30

FREIBURG, Germany, Oct. 12, 2021 /PRNewswire-AsiaNet/ -- Eleva, a manufacturer of superior biologics, is entering clinical phases with its own drug candidates, such as immune-regulating factor H, as well as in collaboration with pharmaceutical partners. Its moss-based platform is ideally suited to produ...

  Sai Life Sciences presents mid-term report on Sai Nxt initiati... - 11 October 2021 20:50

HYDERABAD, India, October 11, 2021 /PRNewswire-AsiaNet/ - - Completes two-thirds of its investment target of US$150M - Demonstrates a leap forward in capabilities across all focus areas – People, Processes, and Infrastructure Sai Life Sciences, a leading global Contract Research, Developm...

  18-Month Below-the-Knee Data with MedAlliance's SELUTION SLR(T... - 11 October 2021 08:00

GENEVA, Oct. 11, 2021 /PRNewswire-AsiaNet/-- 18-month results from the PRESTIGE* Below-the-Knee (BTK) study have been presented as a Late Breaking Clinical Trial at VIVA21. The objective of this clinical investigation has been to evaluate safety and performance outcomes of SELUTION SLR(T...

  Cigna Reaches Agreement With Chubb To Divest Its Life, Acciden... - 08 October 2021 13:04

BLOOMFIELD, Conn., Oct. 8, 2021 /PRNewswire-AsiaNet/ -- -- Agreement will sharpen Cigna's focus on the growth path for its rapidly expanding global health portfolio Cigna Corporation (NYSE:CI), a global health service company, today announced a definitive agreement with Chubb (NYSE: CB) to sell its ...